Global Market Research Report on Ovarian Cancer Drugs Market 2017 is a professional and in-depth complete study on the current state of the Ovarian Cancer Drugs worldwide.

Deerfield Beach, FL -- (SBWire) -- 06/14/2017 --New report on Ovarian Cancer Drugs is cancer that affects the ovaries. According to the WHO, an estimated 2,38,700 women were diagnosed with ovarian cancer in 2012. The report analyzes the demand for ovarian cancer drugs, which would contribute to the growth of the market. It focuses on both generic and brand drugs that are used to treat ovarian cancer and their impact on the market.

The market is driven by the increasing incidence of ovarian cancer. The need for more effective treatment options is pushing growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. Development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treating ovarian cancer.

Get Free Sample Report Of Ovarian Cancer Drugs Market @ http://www.marketresearchstore.com/report/world-ovarian-cancer-drugs-market-opportunities-and-68462#RequestSample

The drugs used to treat ovarian cancer include Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), Gemcitabine Hydrochloride, Platinol-AQ (Cisplatin), Topotecan Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Hycamtin (Topotecan Hydrochloride), Doxorubicin Hydrochloride, LipoDox (Doxorubicin Hydrochloride Liposome), Dox-SL (Doxorubicin Hydrochloride Liposome), Clafen (Cyclophosphamide), Adriamycin RDF (Doxorubicin Hydrochloride), DOXIL (Doxorubicin Hydrochloride Liposome) and others. Treatment for ovarian cancer mostly includes a combination of two drugs, usually a platinum compound (Cisplatin or carboplatin) and a taxane (Paclitaxel or docetaxel). The companies include Roche, Amgen, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and others. In Dec 2011, Roche received EU approval for it drug Avastin (bevacizumab) to be used in combination with carboplatin and paclitaxel as treatment for ovarian cancer.

Do Inquiry To Buy Report Of Ovarian Cancer Drugs Market @ http://www.marketresearchstore.com/report/world-ovarian-cancer-drugs-market-opportunities-and-68462#InquiryForBuying

BY DRUG

-Paclitaxel
-Cisplatin
-Adriamycin PFS (Doxorubicin Hydrochloride)
-Carboplatin
-Cyclophosphamide
-Platinol (Cisplatin)
-Paraplatin (Carboplatin)
-Doxorubicin Hydrochloride Liposome
-Gemzar (Gemcitabine Hydrochloride)
-Hycamtin (Topotecan Hydrochloride)
-Doxorubicin Hydrochloride
-LipoDox (Doxorubicin Hydrochloride Liposome)
-Dox-SL (Doxorubicin Hydrochloride Liposome)
-Clafen (Cyclophosphamide)
-Adriamycin RDF (Doxorubicin Hydrochloride)
-DOXIL (Doxorubicin Hydrochloride Liposome)

BY GEOGRAPHY

-North America
-Europe
-Asia Pacific
-LAMEA